Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
• Renal and fecal excretion of the oral dose of chemistry, ecotoxicology, virology, micro- would be difficult to manage because of the
OE-P is in its active antiviral form OC (F. biology, enzymology, hydrology, public migratory nature of the hosts.
Hoffmann-La Roche 2007) health protection, and wastewater engineering Further pandemics could be avoided with a
• Negligible biotransformation of OC in were invited to participate. The pharmaceuti- concerted research effort including robust pre-
sewage treatment plants (STPs) [European cal industry, the water industry, and central paredness plans, especially the use of antivirals.
Medicines Agency (EMEA) 2005; Fick 2007] government were represented, together with a The proportion of the population receiving
• Low sorption of OC into sewage sludge wide variety of organizations advising and Tamiflu could be higher than the 25% consid-
(low Log P) and high water solubility supporting these sectors. ered by Singer et al. (2007). Although it is
(F. Hoffmann-La Roche 2007) inevitable that drug-resistant forms of the
• Negligible biodegradation of OC in river Overview influenza virus will occur, strains of influenza
water (Accinelli et al. 2007) To ensure that all participants had the knowl- that are resistant to pharmaceuticals have been
• Insufficient dilution of OC in many of the edge base required, plenary talks provided an found to have compromised biological fitness
examined receiving river waters to obviate overview of the current understanding of the (Aoki et al. 2007).
ecotoxicologic risks (Singer et al. 2007). processes and hazards associated with OC The principles of environmental assess-
Preliminary hazard characterization. It release to the environment. ment processes have been reported by the
has been suggested that the release of OC into In selected U.S. and U.K. catchments dur- EMEA (2006). Regarding the current regula-
rivers generates OC resistance in avian ing an influenza pandemic, the predicted envi- tory framework for predicted no-effect con-
influenza in wildfowl (Singer et al. 2007). OC ronmental concentration (PEC) of OC centration (PNEC) and PEC assessments for
could enter the gut of wildfowl from ingested depends on population size and liters of river human pharmaceuticals in various countries,
river water and interact with the avian water available for dilution of sewage effluent Europe emphasizes chronic effects assessment
influenza neuraminidase. The concentration per capita. Concentrations of OC in catch- in algae, crustaceans, and fish, whereas the
of OC in the gut might be higher than in ments with particularly low flow and high United States focuses on the assessment of
river water owing to recycling of the urine in populations are predicted to be > 20 µg/L, acute effects. The European Centre for
waterfowl, thereby further increasing the which is significantly higher than that observed Ecotoxicology & Toxicology of Chemicals
selection pressure for OC resistance. for most other pharmaceutical contaminants. (ECETOC 2007) argues for intelligent strate-
The workshop, Tamiflu and the Environ- OC may possibly affect the function and sta- gies for chronic ecotoxicity testing that reflects
ment: Implications of Use under Pandemic bility of sewage treatment plants (STPs) as a the mode-of-action protein target(s) of a given
Conditions, was designed to further charac- result of the inhibition of floc or biofilm for- chemical (e.g., agrochemical, biocide, pharma-
terize the hazards and risks associated with mation, as these microbial growth forms are ceutical). For example, chronic testing of
the projected scale of Tamiflu release to the integral to process stability and functionality. estrogenic drugs should include aquatic ani-
environment during a pandemic, as well as to Because a mixture of pharmaceuticals— mal species that are known to have estrogen
identify priorities for further research. It was particularly antibiotics—is likely to pass receptors. Wider use of the mode-of-action
recognized by the workshop’s organizers that through STPs during a pandemic, the risk of intelligent testing strategy approach as an
a holistic assessment of risks could be made inhibition of floc or biofilm formation could alternative to routine lethality testing would
best by bringing together diverse experts and be even greater. Also, the generation of OC provide important animal welfare and eco-
organizations with relevant experience. resistance in avian influenza–infected wildfowl nomic benefits while simultaneously providing
Accordingly, experts in environmental after exposure to OC-contaminated river water a sound scientific rationale for calculating
PNECs for OE-P, OC, and other important
60
human pharmaceuticals.
Unpublished results from ongoing
Organisation for Economic Co-operation and
Percent coverage based on treatment
pu a
nm ic
J rk
rm n
e y
Fin den
Al and
I ia
rtu l
Sp al
ite M in
S a
Si ove s
Ho ap a
K e
l g
Ne M gium
Ne Zea cau
er nd
Q s
Ic atar
Sw Nor nd
er y
Lu Ku nd
bo t
Ir urg
st d
ite A ralia
ng ia
Fr om
ce
ec Ca wan
Po srae
m ai
Sw an
Sl tate
nd
itz wa
Re d
Ge apa
d alt
ng ni
ng or
Be on
Au elan
De bl
g
a
Ki tr
a
pr
ee
h na
th la
la
xe w
an
ge
d us
I
la
l
w a
el
i
Un
and performed under Good Laboratory River water pollution with pharmaceuticals Antiviral resistance. Workshop partici-
Practice quality assurance. The preliminary no is relevant in the United Kingdom, particularly pants were uncertain about the potential for
observed effects concentrations (NOECs) in England, because it is a densely populated, generation of OC resistance in avian influenza
resulted in a PNEC of 100 µg/L, applying an small island with relatively short low-flow viruses as a result of the exposure of wildfowl
assessment factor of 10. This PNEC is higher rivers (Keller et al. 2006). More precise model- to OC in surface waters. Concerns were some-
than published PECs (Singer et al. 2007) or ing is needed to determine specific locations what alleviated by the knowledge that OC is
those newly calculated using worst-case pan- where local risks to water pollution are greatest. not readily absorbed from the gut and there-
demic use assumptions and various algorithms. Hydrologic and demographic factors in the fore should not be present in significant
Hence, based on recognized environmental risk United Kingdom indicate that the Midlands, amounts in the urine to recycle, as proposed by
assessment procedures as detailed in the Thames, and Anglian regions of England are Singer et al. (2007). The consensus opinion
European Union Technical Guidance Document likely at highest risk. was that it is difficult to predict the exposure of
on Risk Assessment (European Commission OC in the wild fowl gut and its implications
2003), risk from OE-P and OC in the scenarios Aim and Objectives for hastening the generation of OC-resistance
presented appear to be negligible, including the The aim of the workshop was to assess the in avian influenza. However, attending virolo-
low-dilution scenario in the River Lee in the implications of Tamiflu release to the environ- gists agreed that reassortment, or mutation,
United Kingdom (Singer et al. 2007). ment following mass administration under pan- would be required to generate a virus with
The U.K. Environment Agency does not demic conditions, and to identify any further human specificity, and such viruses would have
have any role in the licensing of human actions required to minimize risks to human to find a path to circulate back to humans. The
pharmaceuticals or the environmental safety and environmental health. actual risk to the human population is unlikely
assessments required by the regulatory process. Four multidisciplinary working groups to be significant. Nevertheless, the possibility
In the United Kingdom the responsibility for addressed the following questions: of OC resistance arising in influenza viruses in
issuing licenses lies with the Medicines and 1. Does current knowledge about Tamiflu waterfowl, although unlikely, cannot be cate-
Healthcare products Regulatory Agency release to the environment provide suffi- gorically ruled out. Thus, it is important to
(MHRA). Furthermore, the Environment cient assurance of safety for human health consider the consequences if resistant viruses
Agency has no advisory role in this process. By and the environment? should evolve (be selected).
contrast, the Environment Agency acts as an 2. What are the research needs to ensure that The highest concentrations of OC in river
advisor to the relevant competent authorities the risks associated with Tamiflu release to water will be reached only during relatively
for pesticides, biocides, and veterinary pharma- the environment can be better understood, short spells of very high drug usage during an
ceuticals for issues relating to environmental minimized, or mitigated? influenza pandemic. This can occur only after
safety. The program of work on human 3. Of any research requirements identified, thousands of infected patients have been
pharmaceuticals lies within the Environment what are the priority research tasks? treated with the drug. Resistant viruses will
Agency’s responsibility for assessing and report- 4. What are the long-term issues triggered by, inevitably evolve in some of these patients in
ing on the state of the environment, as well as or associated with, the issue of Tamiflu advance of any possible selection in waterfowl.
identifying possible environmental concerns. release to the environment? Thus, should the waterfowl be infected with
This work includes a screening process used to the pandemic strain, the resistant virus strains
rank pharmaceuticals based on their relative Results and genetic mutations encoding OC resistance
risk to the aquatic environment (Environment Workgroup members were asked to quantify selected will be common to both species but
Agency 2003, 2008) and a short, targeted their assurance of safety with the present selected in humans first. A resistant pandemic
monitoring program conducted for a number knowledge base on Tamiflu release to the virus in waterfowl, alongside the same viruses
of the higher-priority pharmaceuticals environment on a scale of 1–5 (where 1 = low already in humans, will have little or no effect
(Environment Agency 2003). OE-P was not assurance of safety and 5 = high assurance of on the human situation. Similar to the situa-
included in the screening process because of its safety). The mean ± SD rating for the four tion in humans, resistant viruses in waterfowl
low usage in the United Kingdom for routine working group sessions was 3.3 ± 0.3. are likely to be cleared or revert to wild-type
treatment. The Environment Agency therefore The highest priority knowledge gaps iden- once river OC levels fall and the selection pres-
conducted a separate assessment for use under tified by participants fell into four main areas: sure is removed. Available data regarding the
pandemic conditions, drawing on public a) ecotoxicologic effects; b) antiviral resis- nature of OC resistance indicate that muta-
information sources. Exposure was estimated tance; c) STP failure, particularly as a result of tions responsible for conferring resistance
for treatment only and for treatment plus pro- nontarget neuraminidase inhibition (e.g., severely compromise viral growth and infectiv-
phylaxis, using assumptions from Singer et al. microorganisms); and d) exposure models to ity (Aoki et al. 2007; Chutinimitkul et al.
(2007) and modified assumptions from the define realistic worst-case scenarios for envi- 2007; Hayden 2006; Hurt et al. 2007; Lipsitch
Department of Health based on treatment of ronmental exposure. et al. 2007; Yen et al. 2005). If resistance were
50% of the population with Tamiflu and pro- Ecotoxicity. Most participants concluded selected or acquired by reassortment in other
phylaxis (Scientific Pandemic Influenza that the ecotoxicity of OE-P and OC was not avian virus strains, again the resistant viruses
Advisory Committe 2008). Based on available likely to be an area of primary concern based would likely revert to wild-type once selection
data, risk to the aquatic environment from on preliminary data (Straub JO, personal com- pressure was removed. If for some reason this
OE-P and OC appeared low. However, this munication). Many participants expressed a did not happen and the resistant virus persisted
requires further investigation for catchments desire to see a broader range of ecotoxicologic as one of the avian virus strains circulating in
with high population and low dilution of work conducted and published in peer- waterfowl, then its chance of becoming a
sewage effluents in surface waters. The reviewed journals. However, the level of con- human pathogen (by chance mutation or
Environment Agency will review new data cern regarding the ecotoxicity was generally recombination) would be no greater than that
generated on fate and effects of OC (e.g., by quite low. Considerably greater concern was for any of the other 16 avian influenza A virus
F. Hoffmann-La Roche) before reaching any expressed regarding the potential inhibition of serotypes in circulation. Such events are rare;
further conclusions (T. Boucard, personal nontarget neuraminidases in organisms other highly pathogenic H5N1 viruses have been cir-
communication). than influenza viruses (e.g., microorganisms). culating and infecting the occasional human
who has direct contact with birds since 1997, consequences, as untreated sewage entering First, should additional tests be performed on
and the virus has still not achieved the capabil- rivers would kill a large number of the aquatic “nontarget” organisms (e.g., bacteria) and sce-
ity of transmitting between humans. Thus, the organisms and be an additional threat to narios (e.g., STPs) based on the mode of
idea of a “second wave” pandemic arising by human health. Another concern is that action? Second, should the environmental
this mechanism is considered highly unlikely. restarting sewage works with fresh cultures is safety of pharmaceuticals be specifically evalu-
There is concern that nonpandemic strains a difficult process. ated for pandemic scenarios, where appropriate?
might not be a good predictor of how a pan- Exposure models. One example of routine The assessment of pharmaceutical release
demic strain of influenza could develop, use of OE-P for seasonal influenza is Japan, to the environment, particularly that projected
because the possibility of developing compen- which maintains the highest use of NAIs of to occur under epidemic or pandemic condi-
satory mutations could allow an OC-resistant any country in the world. Greater than 90% of tions, requires the integration of a diverse
pandemic strain to grow and infect in an the prescriptions for seasonal influenza in range of scientific expertise across a range of
uncompromised manner. There appears to be Japan are for OE-P (Moscona and McKimm- public and private organizations. As part of
a gap between the perceptions of nonvirologists Breschkin 2007). Sewage works in Japan have this, national environmental regulators should
working in this field and the views expressed been processing OC from 5–10% population play a more active role informing international
by virologists that emergence of resistance is treatment per annum for > 4 years. There is and national authorities governing pharma-
unlikely to pose a threat. concern regarding this use pattern and whether ceutical use. Clearly, the implications for the
STP failure. In the event of an influenza sufficient OC is released into rivers within water industry of potentially large quantities of
pandemic, STPs will receive approximately Japan to generate an OC-resistant strain even antimicrobial products entering STPs need to
10-fold higher concentrations of OC (and before the onset of a pandemic. However, the be assessed more carefully.
other antiviral or antimicrobial compounds) risk posed by the generation of OC-resistance The risk scenarios proposed here are not
than is projected to occur in rivers (Singer et al. in the environment from OC-containing unique to Tamiflu or to an influenza pan-
2007), because the STP effluent is diluted by sewage effluent is likely to be low, for the demic, but to all future epidemics and pan-
river flow. This higher concentrations will pose aforementioned reasons. Japan might provide demics. Hence, the output of the workshop
a widespread problem to STPs if these com- an opportunity to test the validity of the model provides an initial effort toward developing
pounds inhibit the process organisms during a systems used to predict river levels of OC dur- fully integrated preparedness plans that con-
pandemic. One of the concerns is that OC ing high drug usage and to examine the long sider all facets of human and environmental
might exhibit activity on neuraminidases pro- term effect of high OC levels on sewage treat- health.
duced by bacteria within STPs. Because there ment efficiency and biofilms in real life situa-
are potential analogous receptors that might tions. Swabbing of wildfowl in Japan for Recommendations
respond to the release of Tamiflu, it would be OC-resistant virus could be conducted to Recommendations from Tamiflu and the
prudent to assess the nontarget “activity” of the detect resistance events, but as these are likely Environment: Implications of Use under
drug. Tamiflu is an NAI that was rationally to be rare, the results of such a study would be Pandemic Conditions are as follows:
designed to inhibit the influenza A and B neu- equivocal without very high sample numbers. • The vulnerability of STPs should be exam-
raminidase; however, there is a basis for consid- ined regarding exposure to the predicted
ering that a neuraminidase present in a Conclusions concentrations of OC and antibiotics during
bacterium could also be inhibited by Tamiflu. By assembling a wide range of relevant exper- a pandemic.
Soong et al. (2006) demonstrated the efficacy tise, Tamiflu and the Environment: Implica- • All newly generated environmental fate and
of OC and a similar antiviral, peramivir, to tions of Use under Pandemic Conditions ecotoxicologic data for OC and OE-P, along
inhibit biofilm formation in the microorgan- provided a unique opportunity to make a pre- with an environmental risk assessment,
ism Pseudomonas aeruginosa. These authors liminary holistic assessment of whether safety should be collated and published in a peer-
were interested in the potential to use the NAI for the environment and human health can be reviewed scientific journal.
for alleviating symptoms of cystic fibrosis, assured if Tamiflu is used under pandemic • More detailed models should be used to
hence they did not investigate environmentally conditions. Although questions of safety assur- assess the highest likely environmental con-
relevant concentrations of OC. Nevertheless, ance depend on professional judgment, the centrations of OC and associated anti-
they found that 1 µg/L OC demonstrated a consensus of this workshop was that OE-P microbials both in STPs and in catchments
0.6-fold inhibition of biofilm formation, which and OC release into the environment might known to have low dilution.
might be applicable to concentrations in STPs still pose risks associated with the generation
during an influenza pandemic (Soong et al. of antiviral resistance or destabilization of CORRECTION
2006). This demonstration of the importance microbial biofilms that are key to the perfor-
of bacterial neuraminidases in biofilm forma- mance and function of STPs. The risk of OC In the manuscript originally published
tion indicates the possible vulnerability of STP resistance in wildfowl seems to be less signifi- online, the listing of authors was inaccurate.
biofilms to OC exposure during a pandemic. cant than the effects of mixtures of pharma- It has been corrected here.
There are additional concerns regarding STP ceuticals in sewage and the sewage treatment
failure because of the potential scale of anti- process. This is a critical issue given the
biotic use to treat secondary infections stem- unprecedented quantities of analgesics, anti- REFERENCES
ming from influenza-infected patients, inflammatory drugs, antipyretics, antibiotics,
although the use of antivirals might decrease and antivirals likely to be used in a pandemic. Accinelli C, Caracciolo AB, Grenni P. 2007. Degradation of the
antiviral drug oseltamivir carboxylate in surface water
the need for antibiotic use (Kaiser et al. 2003; The case of seasonal use of Tamiflu in Japan samples. Int J Environ Anal Chem 87(8):579–587.
Nicholson et al. 2000; Treanor et al. 2000; might provide a valuable surrogate for assess- Anonymous. 2007. Levels of resistance to oseltamivir remain
Whitley et al. 2000). ing the implications of release under pandemic low in community isolates of influenza virus in Japan.
Inpharma 1:19.
Changes in activated sludge floc integrity conditions, as well as validating models. Aoki FY, Boivin G, Roberts N. 2007. Influenza virus susceptibility
or the biofilms in trickling filter works could Potential inhibition of microbial neu- and resistance to oseltamivir. Antivir Ther 12(4 PtB):603–616.
lead to a loss of effective sewage treatment. raminidases raised additional questions pertain- Chutinimitkul S, Suwannakarn K, Chieochansin T, Mai LQ,
Damrongwatanapokin S, Chaisingh A, et al. 2007. H5N1
This would have catastrophic environmental ing to the pharmaceutical regulatory process:
Oseltamivir-resistance detection by real-time PCR using of resistance by influenza A virus. PLoS ONE 2(10):e986; Scientific Pandemic Influenza Advisory Committee. 2008. Statement
two high sensitivity labeled TaqMan probes. J Virol doi:10.1371/journal.pone.0000986 [Online 3 October 2007]. Providing Scientific Advice on Stockpiling Neuraminidase
Methods 139(1): 44–49. Hayden FG. 2006. Antivirals for influenza: historical perspectives Inhibitors. Available: http://www.advisorybodies.doh.gov.uk/
Department of Health and Human Services. 2006. Pandemic and lessons learned. Antiviral Res 71(2-3):372–378. spi/spi2008-01neuraminidasestockpiling.pdf [accessed
Planning Update: A Report from Secretary Michael O. Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG. 16 July 2008].
Leavitt, March 13, 2006. Available: http://www.hhs.gov/ 2007. Susceptibility of highly pathogenic A(H5N1) avian Singer AC, Nunn MA, Gould EA, Johnson AC. 2007. Potential
panflu20060313.pdf [accessed 30 September 2008]. influenza viruses to the neuraminidase inhibitors and risks associated with the widespread use of Tamiflu.
ECETOC. 2007. Intelligent Testing Strategies in Ecotoxicology: adamantanes. Antiviral Res 73(3):228–231. Environ Health Perspect 115:102–106.
Mode of Action Approach for Specifically Acting Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. 2003. Smee DF, Sidwell RW. 2002. Peramivir (BCX-1812, RWJ-270201):
Chemicals. Technical Report 102. Brussels:European Centre Impact of oseltamivir treatment on influenza-related lower potential new therapy for influenza. Expert Opin Investig
for Ecotoxicology and Toxicology of Chemicals. Available: respiratory tract complications and hospitalizations. Arch Drugs 11(6):859–869.
http://staging.idweaver.com/ECETOC/Documents/ Intern Med 163(14):1667–1672. Soong G, Muir A, Gomez MI, Waks J, Reddy B, Planet P, et al.
TR%20102.pdf [accessed 30 September 2008]. Keller VDJ, Whelan MJ, Rees HG. 2006. A global assessment of 2006. Bacterial neuraminidase facilitates mucosal infection
EISS (European Influenza Surveillance Scheme). 2007. Pandemic chemical effluent dilution capacities from a macro-scale by participating in biofilm production. J Clin Invest
Plans on the Internet. Available: http://www.eiss.org/ hydrological model. In: Climate Variability and Change— 116(8):2297–2305.
html/pandemic_plans.html [accessed 30 September 2008]. Hydrological Impacts. IAHS Publication no. 308. Wallingford, Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R,
EMEA (European Medicines Agency). 2005. Tamiflu: European UK:IAHS Press, Institute of Hydrology, 586–590. Riff D, et al. 2000. Efficacy and safety of the oral neu-
Public Assessment Report. Available: http://www.emea. Lipsitch M, Cohen T, Murray M, Levin BR. 2007. Antiviral raminidase inhibitor oseltamivir in treating acute influenza:
europa.eu/humandocs/Humans/EPAR/tamiflu/tamiflu.htm Resistance and the Control of Pandemic Influenza. PLoS a randomized controlled trial. JAMA 283(8):1016–1024.
[accessed 15 May 2008]. Med 4(1):e15; doi:10.1371/journal.pmed.0040015 [Online Ward P, Small I, Smith J, Suter P, Dutkowski R. 2005.
EMEA (European Medicines Agency). 2006. Guideline on the 23 January 2007]. Oseltamivir (Tamiflu®) and its potential for use in the
Environmental Risk Assessment of Medicinal Products for Moscona A, McKimm-Breschkin J. 2007. News about influenza B event of an influenza pandemic. J Antimicrob Chemother
Human Use. EMEA/CHMP/SWP/4447/00. Available: http:// drug resistance that cannot be ignored [Editorial]. JAMA 55(suppl 1):i5–i21.
www.emea.europa.eu/pdfs/human/swp/444700en.pdf 297(13):1492–1493. Whitley RJ, Hayden RG, Reisinger KS, Young N, Dutkowski R,
[accessed 1 October 2008]. Mounier-Jack S, Jas R, Coker R. 2007. Progress and shortcomings Ipe D, et al. 2000. Oral oseltamivir treatment of influenza in
Environment Agency. 2003. Targeted Monitoring Programme for in European national strategic plans for pandemic influenza. children. Pediatr Infect Dis J 20(2):127–133.
Pharmaceuticals in the Aquatic Environment. Bristol, Bull WHO 85(12):923–929. WHO (World Health Organization). 2006a. WHO Rapid Advice
UK:Environment Agency. Nicholson KG, Aoki FY, Osterhaus ADME, Trottier S, Guidelines on pharmacological management of humans
Environment Agency. 2008. Prioritisation of Pharmaceuticals of Carewicz O, Mercier CH, et al. 2000. Efficacy and safety of infected with avian influenza A (H5N1) virus (May 2006).
Potential Environmental Concern. R&D Technical Report. oseltamivir in treatment of acute influenza: a randomised Available: http://www.who.int/csr/disease/avian_influenza/
Bristol, UK:Environment Agency. controlled trial. Lancet 355:1845–1850. guidelines/pharmamanagement/en/index.html [accessed
European Commission. 2003. Technical Guidance Document on OECD. 1984. OECD Guidelines for Testing of Chemicals: Alga, 1 October 2008].
Risk Assessment. Commission Directive 93/67/EEC, Growth Inhibition Test. OECD TG 201. In: Annex I: OECD Test WHO (World Health Organization). 2006b. Pandemic Influenza
Commission Regulation (EC) No 1488/94, Directive 98/8/EC Guidelines for Studies Included in the SIDS. Available: Draft Protocol for Rapid Response and Containment (Updated
Available: http://ecb.jrc.it/tgd/ [accessed 17 April 2008]. http://www.oecd.org/dataoecd/17/22/1948257.pdf [accessed Draft 17 March 2006). Available: http://www.who.int/csr/
F. Hoffmann-La Roche. 2007. Tamiflu: Pharmacological properties. 7 October 2008]. disease/avian_influenza/guidelines/pandemicfluprotocol_
Available: http://emc.medicines.org.uk/emc/assets/c/html/ OECD. 1992. OECD Guidelines for Testing of Chemicals: Fish, 17.03a.pdf [accessed 30 September 2008].
DisplayDoc.asp?DocumentID=10701#PHARMACOLOGICAL_ Early Life Stage Toxicity Test. OECD TG 210' In: Annex I: WHO. 2007. Clinical Management of Human Infection with
PROPS [accessed 30 September 2008]. OECD Test Guidelines for Studies Included in the SIDS. Avian Influenza A (H5N1) Virus (updated advice 15 August
Ferguson NM, Cummings DAT, Fraser C, Cajka JC, Cooley PC, Available:http://www.oecd.org/dataoecd/17/62/1948269. 2007). Available: http://www.who.int/csr/disease/
Burke DS. 2006. Strategies for mitigating an influenza pan- pdf [accessed 7 October 2008]. avian_influenza/guidelines/ClinicalManagement07.pdf
demic. Nature 442(7101): 448–452. OECD. 1998. OECD Guidelines for Testing of Chemicals: Daphnia [accessed 1 October 2008].
Ferraris O, Kessler N, Lina B. 2005. Sensitivity of influenza magna Reproduction Test. OECD TG 211. In: Annex I: OECD Yen H-L, Herlocher LM, Hoffmann E, Matrosovich MN,
viruses to zanamivir and oseltamivir: a study performed on Test Guidelines for Studies Included in the SIDS. Available: Monto AS, Webster RG, et al. 2005. Neuraminidase
viruses circulating in France prior to the introduction of http://www.oecd.org/dataoecd/17/63/1948277.pdf [accessed inhibitor-resistant influenza viruses may differ substantially
neuraminidase inhibitors in clinical practice. Antiviral Res 7 October 2008]. in fitness and transmissibility. Antimicrob Agents
68(1):43–48. Roberts NA. 2001. Treatment of influenza with neuraminidase Chemother 49(10):4075–4084.
Fick J. 2007. Antiviral oseltamivir is not removed or degraded in inhibitors: virological implications. Phil Trans R Soc Lond B
normal sewage water treatment: implications for development 356(1416):1895–1897.